Clinical and economic outcomes of a 'high-touch' clinical management program for intravenous immunoglobulin therapy

Autor: Zhu J, Kirkham HS, Ayer G, Chen CC, Wade RL, Karkare SU, Robson CH, Orange JS

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 10, Pp 1-12 (2017)

Julia Zhu,1 Heather S Kirkham,1 Gretchen Ayer,2 Chi-Chang Chen,3 Rolin L Wade,3 Swapna U Karkare,4 Chester H Robson,1 Jordan S Orange5 1Walgreens, Deerfield, 2Option Care, Bannockburn, IL, 3Quintiles IMS, Plymouth Meeting, PA, 4Quintiles IMS, Deerfie

Externí odkaz: https://doaj.org/article/b1c57c5dd24d43ab93cda4d8751263a4

PHP20 PSYCHOTROPIC DRUG UTILIZATION PATTERNS AMONG ELDERLY NURSING HOME RESIDENTS IN THE UNITED STATES

Autor: Bhattacharjee, S, Karkare, SU, Kamble, P, Aparasu, R

Publikováno v: In Value in Health 2010 13(3):A85-A85

Preoperative intravenous meloxicam for moderate-to-severe pain in the immediate post-operative period: a Phase IIIb randomized clinical trial in 55 patients undergoing primary open or laparoscopic colorectal surgery with bowel resection and/or anastomosis.

Autor: Silinsky JD; Department of Surgery, Tulane University, New Orleans, LA, 70112, USA., Marcet JE; Department of Surgery, Tampa General Hospital, Tampa, FL, 33606, USA., Anupindi VR; IQVIA, Falls Church, VA, 22042, USA., Karkare SU; IQVIA, Falls Church, VA, 22042, USA., Shah DR; IQVIA, Falls Church, VA, 22042, USA., Mack RJ; Baudax Bio Inc., Malvern, PA, 19355, USA., McCallum SW; Baudax Bio Inc., Malvern, PA, 19355, USA., Du W; Clinical Statistics Consulting, Blue Bell, PA, 19422, USA., Freyer A; Baudax Bio Inc., Malvern, PA, 19355, USA., Black LK; Baudax Bio Inc., Malvern, PA, 19355, USA.

Publikováno v: Pain management [Pain Manag] 2021 Jan; Vol. 11 (1), pp. 9-21. Date of Electronic Publication: 2020 Oct 23.

Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes.

Autor: Zhou FL; Sanofi US, Bridgewater, New Jersey, USA., Yeaw J; IQVIA, Fairfax, Virginia, USA., Karkare SU; IQVIA, Fairfax, Virginia, USA., DeKoven M; IQVIA, Fairfax, Virginia, USA., Berhanu P; Sanofi US, Bridgewater, New Jersey, USA., Reid T; Mercyhealth, Janesville, Wisconsin, USA.

Publikováno v: BMJ open diabetes research & care [BMJ Open Diabetes Res Care] 2018 Dec 22; Vol. 6 (1), pp. e000593. Date of Electronic Publication: 2018 Dec 22 (Print Publication: 2018).

Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.

Autor: Bergvall N; Novartis Pharma AG, Basel, Switzerland., Makin C; IMS Health, Plymouth Meeting, Pennsylvania, United States of America., Lahoz R; Novartis Pharma AG, Basel, Switzerland., Agashivala N; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America., Pradhan A; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America., Capkun G; Novartis Pharma AG, Basel, Switzerland., Petrilla AA; IMS Health, Plymouth Meeting, Pennsylvania, United States of America., Karkare SU; IMS Health, Plymouth Meeting, Pennsylvania, United States of America., McGuiness CB; IMS Health, Plymouth Meeting, Pennsylvania, United States of America., Korn JR; IMS Health, Plymouth Meeting, Pennsylvania, United States of America.

Publikováno v: PloS one [PLoS One] 2014 Feb 06; Vol. 9 (2), pp. e88472. Date of Electronic Publication: 2014 Feb 06 (Print Publication: 2014).